Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Indulgence
Premium
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
Lupin recieves USFDA nod to market generic anthelmintic tablets
According to IQVIA MAT April 2020 data, Albendazole tablets had an annual sales of around $34 million in the US, Lupin said
US FDA grants orphan drug status to mexiletine hydrochloride: Lupin
The Mumbai-based company's drug NaMuscula (mexiletine hydrochloride) is the first and only licensed product to treat myotonia in adults with non-dystrophic myotonic (NDM) disorders
Lupin Q4 net profit up 35% to Rs 390 cr on robust sales, lower tax expenses
In the current times, Lupin has been able to ensure business continuity while safeguarding the health and safety of its employees
Japan's drug regulator PMDA completes inspection of Lupin's Goa facility
The inspection was conducted between September 24 and 27, it added.
Drug maker Lupin receives three observations from US health regulator
The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement
Lupin forays into OTC segment; eyes Rs 3-bn turnover in 5 years
Lupin, one of the top five pharma companies in the country, plans to launch a variety of products across various categories
